Tag: arteriovenous grafts

avg haemodialysis access

A raft of new directions for vascular access grafts

A departure from the “extreme mantra” of Fistula First unlocks the door to a new, dynamic vision that could swing the pendulum back to...

Not always ‘the alternative’: Are arteriovenous grafts unfairly maligned?

The arteriovenous graft (AVG) for use as a dialysis conduit is a story of innovation, disappointment, intrigue, politics and hope. A recent recalibration of...

InnAVasc gains FDA nod for third study phase of investigational haemodialysis...

As per an announcement on the company’s LinkedIn page, InnAVasc Medical has been granted US Food and Drug Administration (FDA) permission to commence the...

Xeltis initiates European first-in-human trial of restorative haemodialysis access graft

Xeltis has announced initiation of a clinical trial evaluating Axess, which it claims is the first ever restorative synthetic haemodialysis access graft. Several patients...
access graft technologies

Bright future for access grafts highlighted at VASBI 2021 with multiple...

New technologies intended to improve the often-mixed outcomes associated with arteriovenous grafts (AVGs) for haemodialysis access were on display at this year’s Vascular Access...
early-cannulation grafts

Early-cannulation grafts display parity with ePTFE options—but also face similar challenges

In addition to demonstrating comparable performance in terms of long-term patency, durability and associated complications, early-cannulation arteriovenous (AV) grafts may hold some advantages when...